NEW data presented yesterday at the Public Health Association of Australia Communicable Diseases & Immunisation Conference has shown that cell-based influenza vaccines were nearly 20% more effective at preventing test-confirmed influenza relative to traditional standard-dose egg-based vaccines, during the 2023-24 United States flu season.
The real-world evidence study analysed data from over 100,000 vaccinated and influenza-tested patients, aged from six months to 64 years old, and compared the odds of testing positive for influenza between cell-based or egg-based vaccine recipients.
Findings showed 19.8% greater protection of cell-based vaccines over standard-dose egg-based vaccines in the prevention of test-confirmed flu, building on similar results over four previous seasons.
Cell-based influenza vaccines are a key innovation in flu prevention and have been available in Australia since 2021.
Cell-based vaccine, Flucelvax Quad, is approved for people aged six months and older and has been listed on the NIP for eligible at-risk people aged five to 64 since 2024.
It will be made in Australia from next year, when the new CSL Seqirus cell-based facility comes online in Melbourne.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Jun 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Jun 25
